

Provider Toolkit

Updated March 2021

Contents

- Background
- Provider Resources
- Patient Resources



Background

- •This toolkit provides Maryland health care professionals with resources and information on monoclonal antibody treatment for COVID-19.
- •Monoclonal antibody treatment (mAb) is not a cure, but it may lessen symptom severity and help keep high-risk patients out of the hospital.



What is Monoclonal Antibody Treatment

- When you are sick, your body makes antibodies on its own to fight the illness.
- Monoclonal antibodies are laboratory-made proteins that mimic natural antibodies' ability to fight viruses, such as COVID-19.



Who Qualifies for Treatment

mAb treatment is for adults and adolescents (12-17 years old) with mild to moderate COVID-19 symptoms who:

- Recently tested positive for COVID-19
- Are within 10 days of first experiencing symptoms
- Do not need to be hospitalized for COVID-19
- Weigh at least 88 pounds



Who Qualifies for Treatment


continued

Are in one of the following high-risk categories:

- Are age 65 and older <u>OR</u> have chronic kidney disease, BMI of 35 or greater, diabetes, or an immunosuppressive disease
- Are age 55 to 64 <u>AND</u> have cardiovascular disease, hypertension, chronic respiratory diseases, or COPD
- For adolescents: high BMI, sickle cell disease, heart disease, neurodevelopmental disorders, a medical-related technological dependence, asthma or other chronic respiratory disease



Treatment Locations in Maryland



As of 2/25/21



Provider Resources



Provider Resources

Resources for Health Care Professional are available at <u>Information</u> <u>about Monoclonal Antibodies (mAb)</u>



Referral and Infusion Location Flyer

Health Care Provider referrals to Monoclonal Antibody Infusions

- Monoclonal antibodies (mAbs) directly neutralize the COVID-19 virus and are intended to prevent the progression of disease
- mAbs are likely to be most beneficial if given to patients early in symptom
- Product delivered via single IV infusion administration
- Early evidence suggest promise of mAb products in outpatient settings to reduce hospitalization

Process to refer your patients

- 1. Review patient eligibility criteria for patients with mild-moderate symptoms. Full criteria listed by FDA:
 - Bamlanivimab
 - Casirivimab and Imdevimab
- 2. Perform a COVID-19 PCR or Point-of-Care

Rapid Antigen Test

(POC Antigen Tests can be supplied by MDH: complete this form if interested).

3. Refer your positive patients to a partnering infusion site* ASAP

to start treatment within 10 days of onset of symptoms.

Option 1 (Preferred) OR Option 2

Send eReferral via the CRISP Unified Landing Page (Starter guide: pp. 1-7, 25-35) Complete referral form (link at top) and submit directly to infusion site

*(Infusion sites listed on next page)

Page 1



Maryland

Health Care Provider Referral to Monoclonal Antibody Infusion Overview and Location Flyer

Updated weekly with new site locations



Referral Options




Option 1:

CRISP eREFERRAL for Monoclonal Antibody Infusion

Access the CRISP mAb eREFERRAL Starter Guide



Referral Options



Option 2:

Maryland Referral Form for Monoclonal Antibody Infusion Treatment



Point-of-Care Rapid Antigen Testing

- Testing provided to practices willing to identify and refer symptomatic patients eligible for mAb therapy
- Interested practices should fill out this <u>Google Form</u> as soon as possible
- After filling out the form, Maryland Department of Health staff will contact you with next steps
- More information is available <u>here</u>



Federal Resources

- HHS COVID-19 Monoclonal Antibody Therapeutics Digital Toolkit
- HHS Therapeutics Distribution Locations
- FDA clinical information about mAb therapeutics:
 - Fact Sheet for Health Care Providers Emergency Use
 Authorization (EUA) of REGEN-COV
 - Bamlanivimab EUA Letter of Authorization Reissue 02092021



Patient Resources



Patient Resources

- FAQs about Monoclonal Antibody Treatment for COVID-19
- Monoclonal Antibody Therapy (mAb) for Treating COVID-19 Fact
 Sheet
- COVID-19 Monoclonal Antibody Treatment for Older Adults in Nursing Homes
- COVID-19 Monoclonal Antibody Therapeutics
- Monoclonal Antibodies Infographic



Social Media - Twitter



Learn more at bit.ly/mAbTreatments

days of symptom onset.





Maryland Department of Health


COVID-19 Treatments

Reduce your risk of hospitalization





Social Media - Facebook





Questions

For more information about mAb, please contact:

Maryland Department of Health

Dr. Howard Haft howard.haft@maryland.gov

Dr. Aliya Jones <u>aliya.jones@maryland.gov</u>

Array Advisors

Clairanne Pesce Clinician Assistance/Outreach for Monoclonal Antibodies covid@array-advisors.com

